Public Sector Pension Investment Board decreased its position in shares of BioTelemetry Inc (NASDAQ:BEAT) by 11.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,143 shares of the medical research company’s stock after selling 10,200 shares during the period. Public Sector Pension Investment Board’s holdings in BioTelemetry were worth $3,525,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in BEAT. Manchester Capital Management LLC bought a new stake in shares of BioTelemetry during the fourth quarter valued at approximately $70,000. Emerald Mutual Fund Advisers Trust bought a new position in BioTelemetry in the fourth quarter valued at approximately $74,000. Exchange Traded Concepts LLC bought a new position in BioTelemetry in the fourth quarter valued at approximately $78,000. Assenagon Asset Management S.A. bought a new position in BioTelemetry in the fourth quarter valued at approximately $202,000. Finally, Everence Capital Management Inc. bought a new position in BioTelemetry in the fourth quarter valued at approximately $210,000. 97.05% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:BEAT traded up $3.96 during midday trading on Thursday, reaching $37.66. 34,153 shares of the company were exchanged, compared to its average volume of 498,490. BioTelemetry Inc has a fifty-two week low of $27.35 and a fifty-two week high of $65.92. The company has a quick ratio of 2.92, a current ratio of 3.02 and a debt-to-equity ratio of 0.52. The stock has a fifty day simple moving average of $44.07 and a two-hundred day simple moving average of $44.63. The firm has a market cap of $1.20 billion, a PE ratio of 46.12, a P/E/G ratio of 1.58 and a beta of 1.43.
BEAT has been the topic of a number of recent research reports. Sidoti reduced their price objective on shares of BioTelemetry from $81.00 to $75.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Zacks Investment Research lowered shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Wednesday, February 26th. Benchmark cut their target price on shares of BioTelemetry from $82.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, March 19th. TheStreet lowered shares of BioTelemetry from a “b-” rating to a “c” rating in a report on Wednesday, February 26th. Finally, BidaskClub lowered shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Friday, March 20th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $64.29.
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Featured Article: How to track put option volume
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.